SARS-CoV-2 Testing Microplate
 Porvair Sciences has introduced a new 2.2-ml 96 deep-well plate that is fully compatible with the Thermo Scientific KingFisher range of nucleic acid purification systems. These systems are reported to drastically reduce processing time and increase productivity. Designed for compatibility and efficiency, each v-shaped bottom well in Porvair’s new plate supports the specialized magnetic tips of all KingFisher instruments, maximizing liquid-sample collection, mixing, and uptake during the purification process, and ensuring reproducible purification of nucleic acids from SARS-CoV-2 patient samples.

Porvair Sciences
For info: 800-552-3696
www.microplates.com/kingfisher-compatible-96-well-microplate

SARS-CoV-2 Monoclonal Antibodies
The Native Antigen Company introduces 10 new monoclonal antibodies recognizing SARS-CoV-2, the causative agent of COVID-19. These antibodies recognize different epitopes of the SARS-CoV-2 spike glycoprotein, nine of which are SARS-CoV-2 specific and do not cross-react with other human coronaviruses; they extend our existing range and offer researchers a source of high-quality reagents for R&D of in vitro diagnostics, therapeutics, and vaccines for COVID-19. The SARS-CoV-2 antibodies were raised using our own S1 and S2 recombinant spike proteins as immunogens. Produced using our proprietary mammalian expression system, these antigens exhibit full glycosylation and proper folding to ensure that antibodies raised against them are highly specific. The antibodies have been screened against our other coronavirus proteins, including SARS, MERS, NL63, OC43, 229E, and HKU1, to demonstrate specificity. Three of the antibodies have been shown to be specific for the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 bound to the cellular angiotensin-converting enzyme 2 (ACE2) receptor.

The Native Antigen Company
For info: +44-(0)-1865-595230
thenativeantigencompany.com

SARS-CoV-2 Antibodies and Antigens
AMS Biotechnology has further expanded its product range to help in the fight against COVID-19, with the introduction of a new range of SARS-CoV-2 antibodies and antigens to aid development of new immunoassay diagnostic kits. A suite of SARS-CoV-2 mutant spike and nucleocapsid antigens is now available. Perfect for use in a wide range of different antibody detection methods, these antigens are customizable and available in bulk. In addition, we have also introduced a new range of matched antibody pairs specifically designed and screened for antigen detection kit development. Verified against inactivated COVID-19 virus samples, these antibody pairs are ideal for development of diagnostic assays, including chemiluminescent immunoassays, ELISAs, and gold immunochromatographic assays (also known as lateral flow assays (LFAs)). The sensitivity of these matched antibody pairs when used in a sandwich ELISA kit has been shown to be as low as 12 pg/mL. The virus titer, which was determined using an LFA, is as low as 102 cell culture infectious dose 50% (CCID50)/mL.

AMS Biotechnology
For info: 617-945-5033
www.amsbio.com/antibodies-antigens-sars-cov-2-diagnostic-kits

PCR Test to Differentiate Between COVID-19 and Flu
EUROIMMUN, a PerkinElmer company, announces the launch of the European Conformity (CE)-marked EURORealTime SARS-CoV-2/Influenza A/B PCR test for direct detection of SARS-CoV-2, influenza virus type A, and influenza virus type B. It expands the testing portfolio for acute COVID-19 diagnostics by supporting differential diagnostics between SARS-CoV-2 infections and the common flu, and is available in countries accepting the CE mark. PCR technology is considered the gold standard for direct pathogen detection. The EURORealTime test allows fast detection and differentiation of genetic material using throat-swab samples of patients with acute symptoms. Validation efforts revealed high agreement of results obtained with the EURORealTime test and those obtained with reference PCR tests for SARS-CoV-2 and influenza A/B. No cross-reactions with other common respiratory pathogens were detected. The assay is compatible with common real-time PCR thermal cyclers, and the EURORealTime Analysis Software allows for reliable, standardized evaluation of test results.

PerkinElmer
For info: 800-762-4000
www.perkinelmer.com

Rapid Antibody Test Kit for SARS-CoV-2
MP Biomedicals Asia Pacific announces the successful development of the ASSURE SARS-CoV-2 IgG/IgM rapid test, a rapid antibody test kit for COVID-19, in collaboration with the Agency for Science, Technology and Research (A*STAR). It produces accurate results in as little as 15 min and employs a lateral flow format similar to those used in home pregnancy tests. The test kit detects immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies, which are produced by the body to combat SARS-CoV-2, from samples of human blood, plasma, or serum. ASSURE should not be used in the clinical diagnosis of COVID-19 infections or in the evaluation of persons with acute respiratory symptoms, especially within the first 14 days of illness. However, ASSURE can help to determine whether an individual has been previously exposed to the virus and has generated antibodies as a result. This can help identify asymptomatic individuals or those with only mild symptoms who were not subjected to reverse transcription-PCR testing.

MP Biomedicals
For info: 800-854-0530
www.mpbio.com/about-us